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Abstract
Monitoring of latent Mycobacterium tuberculosis infection may prevent disease. We tested an ESAT-6 and CFP-10-specific
IFN-c Elispot assay (RD1-Elispot) on 163 HIV-infected individuals living in a TB-endemic setting. An RD1-Elispot was
performed every 3 months for a period of 3–21 months. 62% of RD1-Elispot negative individuals were positive by cultured
Elispot. Fluctuations in T cell response were observed with rates of change ranging from 2150 to +153 spot-forming cells
(SFC)/200,000 PBMC in a 3-month period. To validate these responses we used an RD1-specific real time quantitative PCR
assay for monokine-induced by IFN-c (MIG) and IFN-c inducible protein-10 (IP10) (MIG: r=0.6527, p=0.0114; IP-10:
r=0.6967, p=0.0056; IP-10+MIG: r=0.7055, p=0.0048). During follow-up 30 individuals were placed on ARVs and 4
progressed to active TB. Fluctuations in SFC did not correlate with CD4 count, viral load, treatment initiation, or progression
to active TB. The RD1-Elispot appears to have limited value in this setting.
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Introduction
The identification of latent tuberculosis infection (LTBI) and
preventative therapy is important for TB control, especially in
those most likely to progress to active tuberculosis (TB). In
countries with low rates of tuberculosis those at increased risk of
TB exposure are encouraged to partake of serial testing for latent
Mycobacterium tuberculosis infection (LTBI) [1]. However, the
identification of LTBI in individuals co-infected with HIV in high-
burden TB settings is equally important due to the increased risk
of progression to active TB. Isoniazid (INH) treatment of LTBI is
being promoted as a major TB control strategy by the WHO [2]
and accurate monitoring of LTBI status in HIV and Mycobac-
terium tuberculosis (MTB) co-infected individuals may aid the
improved targeting of INH preventative therapy. Importantly,
longitudinal monitoring of these individuals may enable timely
therapy in those who have progressed, or are in the process of
progressing to active TB. The diagnosis of LTBI requires the
identification of an MTB-specific immunologic response. The
tuberculin skin test (TST) is traditionally used to diagnose LTBI.
However, its sensitivity is greatly reduced in HIV co-infected
individuals due to HIV-induced cutaneous anergy resulting in false
negative results [3,4]. Serial TST testing is rarely performed.
Novel and improved diagnostics for LTBI that are predictive of
the benefit of INH and/or progression to active TB are urgently
required. IFN-c release Assays (T-SPOT.TB (Elispot platform)
and QuantiFERON-TB Gold (Elisa platform)) (IGRAs) have
recently been introduced as a diagnostic for LTBI and are in
regular use in clinical practice in the US, UK and India [5].
IGRAs are reported to perform better in an HIV infected
population compared to the TST [6,7,8,9,10,11]. However, little
is currently known on the best way to interpret serial testing for
LTBI using IGRAs, and this is particularly true for HIV positive
populations living in highly endemic TB settings [12–13] [14,15]
[16,17]. Limited data is also currently available on the predictive
value of IGRAs for progression to active TB and better guidelines
are clearly needed.
In contact investigations, IGRAs have been shown to better
correlate with exposure to active Tuberculosis cases than TST
[18,19,20,21]. It has been suggested that T cell responses, as
detected by IGRAs, correlate with bacterial burden
[22,23,24,25,26]. In addition, serial testing using Quantiferon
Gold in Tube was recently reported as a useful method for the
diagnosis of new LTBI in Dutch military personnel [27]. We
hypothesized that measuring an RD-1 specific immune response
longitudinally by ex vivo IFN-gamma Elispot would be useful to
PLoS ONE | www.plosone.org 1 June 2012 | Volume 7 | Issue 6 | e37920diagnose LTBI, and potentially predict progression to active TB.
Using an in-house RD1- specific IFN-gamma Elispot assay this
study aimed to prospectively monitor the MTB-specific T cell
response in an HIV-infected population with no signs and
symptoms of active TB, and no obvious reference point in time
for exposure to TB.
Methods
Study Participants
163 HIV chronically infected (antiretroviral therapy (ARV)
naı ¨ve) individuals (CD4 T cell count range at baseline =5–1142
cells/ul) without signs and symptoms of active TB were recruited
in Durban, South Africa. Blood samples were taken from all
participants to perform a baseline assessment. All individuals had
subsequent blood draws every 3 months for a period of 3–21
months. All study participants were of South African origin and
presumed to have been BCG vaccinated at birth. Ethical approval
was obtained from McCord Hospital, the University of KwaZulu-
Natal and Massachusetts General Hospital. Written informed
consent was obtained from all study participants.
Elispot Assays
All participants were tested for RD1 (ESAT-6 and CFP-10)-
reactivity using an ex vivo IFN-c Elispot assay (RD1-Elispot) on
fresh PBMC (method described in [28]). ESAT-6 and CFP-10
peptide pools were added at a final peptide concentration of
8 ug/ml. Phytohemagglutinin (PHA) (10 mg/ml) was used as a
positive control. PBMC were plated at 200,000 cells/well and
incubated overnight at 37uC and 5% CO2. All stimulations were
performed in triplicate and reported as the average. RD1-
specific responses were considered positive if the number of spots
per well was four SFC more than negative control wells and this
number was at least twice that in negative control wells. This
pre-defined cut-off point translates into a detection threshold of
20 peptide-specific T cells per million PBMC [6,28] [11]. An
Elispot was considered positive if a positive result was obtained
by stimulation with ESAT-6, CFP-10 or both. An indeterminate
result was one that had a positive control less than 20 SFC per
200,000 PBMC or a negative control greater than 10 SFC per
200,000 PBMC [29]. A conversion was defined as a negative
Elispot followed by a positive Elispot, while a reversion was
considered the opposite [30].
Cultured Elispot
4610
6 PBMCs were cultured with either ESAT-6 or CFP-10
peptide pools at a final peptide concentration of 8 ug/ml, for one
hour at 37uC and 5% CO2. The cells were then plated in R10
media at a concentration of 10
6/2 mL and cultured for 2 weeks at
37uC and 5% CO2. On the third day of culture, 1 mL of the
culture media was replaced with 1 mL R10–50 Media (R10 media
supplemented with 100 units/ul IL-2); the media was refreshed in
this manner every 3 three days. After two weeks, the cells were
washed three times with R10 media, re-plated and allowed to rest
overnight in the incubator. The cells were then washed twice with
R10, counted and a routine RD1-Elispot performed.
RD1-specific qPCR Assay
We used a highly sensitive assay of ESAT-6 and CFP-10-specific
IFN-c production using real time quantitative PCR (qPCR) for
two reporters - monokine-induced by IFN-c (MIG) and the IFN-c
Figure 1. Schematic representation of study results. 163 chronically HIV infected (ARV naı ¨ve) individuals (CD4=5–1142 cells/ul) were recruited
in Durban, South Africa. An RD1-Elispot was performed on PBMC every 3 months for a period of 3–21 months. During the period of follow-up 30
individuals were placed on ARVs and 4 individuals progressed to active TB. Of the 129 individuals who were not placed on ARVs or TB treatment
during follow-up, 5 categories of Elispot kinetics were observed: 45 (35%) individuals were consistently negative at each time-point tested, 22 (17%)
individuals were consistently positive at each time-point tested, 8 (6%) individuals displayed sustained conversions (three or more positive Elispots
after at least one negative Elispot), 11 (9%) individuals displayed transient conversions (one or two positive Elispots between negative plates), and 16
(12%) individuals displayed transient reversions (one or two negative Elispots between positive plates). For 27 (21%) individuals the category is
unknown due to either a lack of interpretable results (e.g. SK 179 had indeterminate Elispots at all 3 time points tested), or the absence of either pre-
baseline samples or further follow-up to determine if observed reversions and conversions are transient or sustained.
doi:10.1371/journal.pone.0037920.g001
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formed as described in Kasprowicz et al [31]. In brief, PBMCs
(10
6 cells/condition) were stimulated with 10 ng/ml recombinant
IFN-c (positive control), 25 ml of R10 media (null), or ESAT-6 and
CFP-10 peptide pools (final peptide concentration of 8 mg/ml) at
37u and 5% CO2 for 16 hours. mRNA extraction was performed
using an RNeasy mini kit (Qiagen); extracted cellular mRNA was
reverse transcribed by RT-PCR using iScript cDNA synthesis kit
(BIORad) using 10 ml of cellular mRNA; and qPCR for MIG,
IP10 and HPRT was performed.
Results
Cross-sectional Assessment of RD1 Reactivity by Ex-vivo
Elispot Suggests that 40% of the HIV+ Individuals have
Latent MTB Infection
Of the 163 baseline Elispots performed, 8 (4.9%) were
indeterminate (6 due to high assay background and 2 due to
failed positive control) (Table S1). In Elispot positive individuals,
the ESAT-6-specific responses ranged from 4–98 spot-forming
cells (SFC) (mean of 19), while the CFP-10 responses ranged from
4–87 SFC (mean of 20). 66 (40%) of the 163 individuals with
evaluable results were found to be ex-vivo IFN-gamma Elispot
positive (indicating suspected LTBI) (Table S1). Interestingly, 18/
66 (27%) of positive patients had RD-1 specific responses within 5
SFC of the cut-off. No significant correlation between CFP-10
SFU and CD4 count (r=20.07185, P=0.3621) and ESAT-6
SFU and CD4 count (r=20.05382, P=0.4950) was found (data
not shown).
Longitudinal Analysis of RD1-specific T Cell Responses by
Elispot Reveals a High Level of T Cell Fluctuation
All study participants were tested by ex vivo RD1-Elispot at
baseline and 3 months later. 157 individuals had subsequent blood
draws every 3 months for a period of up to 21 months (Table S1).
Interestingly, of the 737 Elispots displayed in the data set in Table
S1, 66 (9%) indeterminate assays were reported. Of the 163
participants listed, 30 individuals were placed on ARV treatment
during follow-up, 2 were placed on TB treatment, and 2 were
placed on both ARV and TB treatment. Of the 129 individuals
who were not placed on ARVs or TB treatment during follow-up,
5 categories of Elispot kinetics were observed: 45 (35%) individuals
were consistently negative at each time-point tested, 22 (17%)
individuals were consistently positive at each time-point tested, 8
(6%) individuals displayed sustained conversions (three or more
positive Elispots after at least one negative Elispot), 11 (9%)
individuals displayed transient conversions (one or two positive
Elispots between negative plates), and 16 (12%) individuals
displayed transient reversions (one or two negative Elispots
between positive plates) (Figure 1). For 27 (21%) individuals the
category was unknown due to either a lack of interpretable results,
or the absence of either pre-baseline samples or further follow-up
to determine if observed reversions and conversions were transient
or sustained. Figure 2 A, B, C displays examples of 4 of the main
categories of Elispot kinetics.
The majority of individuals (52%) maintained assay status
throughout the follow-up. However, despite this, significant
fluctuations in SFC were observed. Of those subjects that were
consistently Elispot positive, a range of T-cell fluctuations were
observed over time. For example, SK036 showed a response of 24
Figure 2. Longitudinal MTB-specific T cell profiles and correlation with CD4 count and HIV viral load. Longitudinal Elispot data from
individuals who were not on ARVs for the entire period of follow-up. Figure 2A: Examples of responses from 3 individuals who were ex vivo RD1-
Elispot positive at all time-points during follow-up. Figure 2B: Examples of responses from 3 individuals who displayed an RD1-Elispot conversion that
was sustained during follow-up and examples of responses from 3 individuals who displayed a transient RD1-Elispot conversion during follow-up.
Figure 2C: Examples of responses from 3 individuals who displayed a transient RD1-Elispot reversion during follow-up. Left-hand panel= Elispot data,
right-hand panel = CD4 counts and viral loads.
doi:10.1371/journal.pone.0037920.g002
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then increased again after a further 3 months to 83 SFC, and
subsequently decreased to 34 SFC (figure 2A). This is a fluctuation
of approximately 50 SFC every 3 months. We were unable to
quantify all responses due to particular wells appearing completely
black (‘black-out’), most likely due to an extreme rise in RD1-
specific responses. For those who were consistently Elispot positive,
the maximum change in SFC in a 3-month period was 2150 and
+153 SFC for ESAT-6-specific responses and 245 and +45 SFC
for CFP-10 specific responses. Overall, the change in SFC in a 3-
month time-period ranged from 2150 to +153 SFU for ESAT-6-
specific responses and 288 and +123 SFC for CFP-10 specific
responses.
Of the transient conversions, 11 (55%) had positive responses
that were within 5 SFC of the assay cut-off, indicating that these
borderline responses may be false-positives (highlighting the
obvious but important association between cut-off selection and
assay status). Interestingly, the change in SFC between transition
time-points (i.e. the two time-points over which an Elispot status
change occurs) is statistically different when comparing individuals
displaying transient conversions (mean =8 SFC) and those
displaying sustained conversions (mean =17 SFC) (p=0.0071,
Mann-Whitney t-test). However, if you remove the 6 individuals
that lie within 5 SFC of the cut-off, the difference no longer exists,
indicating that a sub-set of individuals displaying transient
conversions have a change in SFC in the same range as those
with sustained conversions. The change in SFC between transition
time-points for individuals displaying transient reversions ranged
from 23t o237 (mean =213 SFC). Almost 35% of individuals
in our cohort were consistently negative at all time-points despite
living in a TB endemic setting. The observation of borderline
positive results highlights the potential for MTB-specific responses
to occur below the selected assay cut-off and even below the
threshold of the ex vivo RD1-Elispot assay.
RD1-specific Molecular Assay Provides Independent
Support for the Observed RD1-Elispot Fluctuations
The RD1-qPCR has recently been developed, validated and
applied to the detection of MTB-specific responses [31]. To assess
whether the variability in Elispot responses could be validated
using a separate assay platform - and are therefore biologically
valid - the ex vivo Elispot and the qPCR assays were compared
longitudinally. A head-to-head comparison was performed on 14
individuals on samples from 2 time-points 3 months apart. A clear
quantitative correlation was observed between the two assays over
time (figure 3A). Figures 3B and C show examples from two
Figure 3. Longitudinal comparison of the ex vivo RD1- Elispot and the RD1-qPCR assay. A highly sensitive assay of RD1-specific IFN-c
production using real time quantitative PCR (qPCR) for two reporters - monokine-induced by IFN-c (MIG) and the IFN-c inducible protein-10 (IP10)
was compared longitudinally with the ex vivo RD1-Elispot. Figure 3A: A head-to–head comparison was performed on 14 individuals on samples from
2 time-points 3 months apart. A significant correlation was observed between fold change on the RD1 qPCR and change in SFC using the RD1-Elispot.
Figure 3B: Data from SK068. Figure 3C: Data from SK036. Top panel displays RD1-Elispot data and bottom-panel displays RD1-qPCR data.
doi:10.1371/journal.pone.0037920.g003
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conversion. However, this conversion was not observed when
performing the qPCR assay, which was positive at both time-
points, although changing quantitatively, consistent with the
enhanced sensitivity of the qPCR [31].
In vitro-culture Using RD1 Peptide Pools Reveals MTB-
specific Responses that are Below the Threshold of
Detection of the RD1-Elispot
Our results above indicate that many MTB-specific T cell
populations may lie close to (but either side of) the ex vivo RD1-
Figure 4. In- vitro culture reveals RD1-specific T cell responses. Left-hand panel displays ex vivo IFN-gamma Elispot data from 4 individuals
(SK378, SK383, SK167, and SK325) who were ex vivo Elispot negative at 2 time-points 3 months apart. Right-hand panel displays data from the same
individuals following a cultured Elispot (14 day in vitro culture of PBMC with the ESAT-6 or CFP-10 peptides followed by IFN-gamma Elispot). All
individuals had CD4 counts above 250.
doi:10.1371/journal.pone.0037920.g004
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we performed Cultured RD1-Elispots to assess the proportion of
individuals with MTB specific memory responses which were not
detected in the ex vivo RD1-Elispot assay [32,33]. 13 (62%) out of
21 individuals (who were negative by ex vivo RD1- Elispot) were
positive by cultured Elispot (responses ranging from 30–475 SFC/
million PBMC) (data not shown and figure 4). These data indicate
that MTB-specific responses may exist in a large fraction of
individuals who are RD1-Elispot negative.
RD1-specific T Cell Frequencies do not Correlate with
Stage of HIV Disease Progression or ARV Status
Changes in CD4 count were not observed to correlate with
changes in SFC. 32 individuals were placed on ARV therapy
during the period of follow-up (due to a low CD4 count, to
prevent mother-to-child transmission (PMTCT) of the virus, or
as a result of diagnosis of TB). In all cases ARVs did not have a
clear and consistent impact on the RD1-specific response (data
not shown). Figures 5 A and B displays the summary data of 11
individuals who were placed on ARVs and had a consistent cut-
off for all time-points tested. Overall the mean response declined
after the initiation of ARV therapy, however this did not reach
statistical significance (ESAT-6: p=20.1133, CFP-10: p=0.1109
(paired t-test)).
Prospective Monitoring of RD1- specific T Cells
Responses is not Able to Predict Progression to Active TB
Four individuals (SK 169, SK 236, SK 325 and SK 351)
progressed to active TB during the period of follow-up (figure 6).
All four did not show a striking change in RD1-specific responses
upon progression to active TB. However, for SK351 the RD1-
specific T cell response decreased slightly as the individual
progressed to active TB (37 SFC to 19 SFC for ESAT-6, and 91
SFC to 4 SFC for CFP-10). TB treatment initiation was also not
associated with striking changes in SFC. The exception to this was
SK236 were TB treatment was associated with a marked increase
in the CFP-10- specific response (14 SFC to 81 SFC).
Discussion
Knowledge of the kinetics of IGRAs and their significance is
limited and there is no consensus on the clinical utility of serial
Figure 5. Impact of ARVS on the RD1-specific T cell kinetic profile. Figure 5 A–B: Summary of longitudinal data from 11 individuals who were
placed on ARVs and had a consistent cut-off at all time-points tested. Figure 5A: Summary of ESAT-6-specific responses. Figure 5B: Summary of CFP-
10-specific responses. Left-hand panel= data from all 11 individuals. Right-hand panel= Mean response plotted. The mean ESAT-6 spot-forming cells
(SFC) at 3 months prior to ARV initiation was 7, and that for CFP-10 was 5 SFC. These responses declined to 2 SFC for ESAT-6 specific responses and 3
SFC for CFP-10 specific responses. Overall the mean response declined after the initiation of ARV therapy, however this did not reach statistical
significance (ESAT-6: p=20.1133, CFP-10: p=0.1109 (paired t-test)).
doi:10.1371/journal.pone.0037920.g005
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MTB-specific T cell using an RD1-Elispot in an HIV-infected
population living in a highly endemic TB setting, with no obvious
reference point in time for exposure to TB [34,35] [14,15] [16,17].
The province of KwaZulu-Natal has an estimated 1.2 million HIV
positive individuals, an antenatal HIV prevalence of 37.4% and a
TB notification rate of 1094/100,000 population [36,37,38].
We observed 5 main categories of Elispot kinetics: persistently
positive, persistently negative, sustained conversions, transient
conversions, and transient reversions. A significant proportion of
the observed reversions and conversions in our study had
borderline responses raising the issue of whether they result in
non-specific variation in laboratory procedures, or whether they
are a result of a true biological change [39,40]. Elispot reversions
have been reported as more common with low or moderately
positive results [27]. Two recent systemic reviews on reproduc-
ibility and serial testing of health care workers both highlight that
borderline conversions and reversions do occur suggesting that a
simplistic dichotomous cut-off is too simplistic for interpretation of
serial IGRAs [13,40,41]. Veerapathran et al recommend that a
true conversion requires a change from a negative to a positive
result and a minimum 30% increase in the baseline IFN-gamma
response [42]. It is clear that defining appropriate cut-offs and
criteria for assay conversions and reversions is absolutely critical to
ensure that assay interpretation is both accurate and significant
[39,40,42].
In this study we found that responses frequently lie close to the
level of detection of the RD1-Elispot platform, indicating that the
selected standard assay cut-off may misrepresent the level of LTBI
(indicated in this cohort at 40%). The reported prevalence of LTBI
in HIV infected populations ranges from 43% in a cohort from
Zambia (determined by Elispot) to 89% in a cohort of South
Figure 6. Prospective monitoring of RD1- specific IFN-gamma Elispot responses does not predict progression to active TB.
Longitudinal Elispots are shown for SK 169, SK 236, SK325 and SK 351 all of whom progressed to active TB during the follow-up period and 2 of which
(SK 325 and SK 351) were also subsequently placed on ARVS. TB Treatment was initiated shortly after diagnosis of active TB. Longitudinal CD4 and
viral load data is also shown for all 4 individuals.
doi:10.1371/journal.pone.0037920.g006
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qPCR is able to identify RD1-specific responses in individuals who
are RD1-Elispot negative, and the cultured Elispot is able to
amplify RD-1 specific responses in 62% of individuals who are
repeatedly RD1-Elispot negative. It has been suggested that ex
vivo IGRAs detect recent MTB infection i.e. recently activated
lymphocytes (effector memory responses) and not more remote
MTB infection (central memory responses), which is most likely
detected by the cultured Elispot [43,44] [44–45]. The RD1-Elispot
and the RD1-qPCR assays appear to measure similar readouts
(potentially effector memory responses targeting viable bacilli)
although the qPCR assay appears more sensitive [31]. However,
the RD1-Elispot is clearly able to detect MTB-specific responses of
a certain magnitude and, in the absence of signs and symptoms of
active TB, this response is presumably indicative of LTBI. To
conclusively prove the absence of active TB in HIV positive
individuals, sputum samples should be taken for AFB and culture
[46]. Overall, our data suggest that MTB-specific responses lie on
a spectrum, which is extended by cultured Elispot. In the absence
of a gold standard for LTBI it is difficult to understand the
significance of immunological sensitization to TB.
Our results indicate that it is difficult to interpret the
significance of a negative RD1-Elispot result in HIV- positive
individuals living in a highly TB endemic setting. It may indicate
that an individual’s immune system has never encountered
Mycobacterium tuberculosis, that the individual has cleared the
bacterium, that the bacterium is stimulating a low-level RD1-
specific response, or alternatively that the bacterium is in a
dormant state. Transient reversions (and conversions) may be
attributable to exposure to antigen and result as a function of the
MTB life-style e.g. ESAT-6 and CFP-10 may be intermittently
secreted [12]. Interestingly, 8 individuals displayed sustained
conversions and the change in SFU between transition time-points
was similar to a sub-set of individuals with transient conversions. A
sustained conversion may indicate recent infection or bacterial
reactivation. Large fluctuations in IFN-gamma responses were
observed even in individuals who were persistently positive at all
time-points tested. As we observed a clear quantitative correlation
between the RD1-Elispot assay and the RD1-qPCR assay, this
provides support that the observed MTB-specific immune
fluctuations are real and not an artefact of assay performance
and procedures. It is impossible to assess if any of these individuals
were re-exposed or whether the fluctuations are representative of
natural host fluctuations, or host-pathogen interactions. Interest-
ingly, we did not observe a correlation between parameters of HIV
disease progression (CD4 count and viral load) and change in
SFC, indicating that HIV disease status did not impact signifi-
cantly on the observed fluctuations in T cell response [16,17]. In
our study, ARVs were not associated with a change in RD1-
Elispot status.
During the period of follow-up, 4 individuals were diagnosed
with active TB and placed on TB treatment. Progression to active
TB and TB treatment initiation was not associated with any
observable pattern of change in RD1 SFC, nor change in RD1-
assay status. Our results highlight the major issue that a key
obstacle to wider treatment of LTBI is the predictive value of the
currently available diagnostic tests (reviewed in Kasprowicz et al.
In press Journal of Infectious Diseases). A limitation of our study is
the low number of individuals that progressed to active TB. A
further point to consider is that we used a generic version of the
commercially available T-SPOT.TB (Elispot IGRA platform).
In conclusion, here we prospectively monitor MTB-specific
responses in individuals living in a highly TB endemic setting using
the RD1-Elispot. In contrast to previous studies, our study focused
on a HIV positive population with no obvious reference point in
time for exposure to TB. Our results highlight that a negative/
positive cut-off is too simplistic for interpretation of serial RD1-
Elispots [39,40,42]. While the RD1- Elispot is able to detect MTB-
specific responses (and presumed LTBI) our data suggest that these
responses lie on a spectrum, which is extended by cultured Elispot.
It is therefore difficult to interpret the significance of a negative
RD1-Elispot result in this setting. Large fluctuations in IFN-
gamma responses were observed, even in individuals who were
persistently positive at all time-points tested, and were validated by
the RD1-qPCR. HIV disease status did not impact significantly on
the observed fluctuations in T cell response. We find that the
RD1-Elispot fails to clearly detect new MTB infection or predict
progression to active disease. Thus, the RD1-Elispot, as currently
used, appears to have limited value in following HIV positive
individuals living in an area endemic for TB. More studies need to
be performed in order to understand the clinical and biological
significance of fluctuations in MTB-specific T cell responses [47]
[48,49,50]. Regardless, the RD1-Elispot may still be a useful
research tool to identify those with LTBI and facilitate immuno-
logical investigation of novel TB biomarkers in HIV infected
individuals.
Supporting Information
Table S1 Longitudinal Elispot data for 163 study
participants– BO indicates a ‘black out’ (Elispot well is
purple and Spot Forming Cells can’t be individually
counted).
(DOC)
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